Curium Pharma agreed to buy Lantheus in a deal valued up to about $8 billion, combining Curium’s theranostics manufacturing platform with Lantheus’ U.S. radiodiagnostics franchise. The transaction is structured at $102.50 per share up front, with contingent value rights that could raise the effective consideration to about $114.50 per share tied to commercial milestones. Analysts characterized the pairing as “strategically logical,” emphasizing expanded geographic reach and a tighter integration of production capabilities across therapeutic and diagnostic radiopharma assets. For the sector, the step signals continued consolidation around scale and commercialization infrastructure in nuclear medicine. Separately, a Reuters-style summary item bundled the same transaction with additional radiopharma-focused market moves, reflecting investor attention on how supply chains, labeling, and distribution models are shaping the next wave of theranostics growth.